drugset / Trial / NCT01051102

Effect of NN5401 in Japanese Subjects With Type 1 Diabetes

NCT01051102

Phase 1 Completed 21 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Japan. The aim of this clinical trial is to investigate the blood sugar lowering effect of NN5401 (insulin degludec/insulin aspart (IDegAsp)) in Japanese subjects with type 1 diabetes. Each subject will be randomised to one of the two possible treatment sequences (NN5401 followed by biphasic insulin aspart (BIAsp) 30 or biphasic insulin aspart 30 followed by NN5401).

Timeline

Start
2010-01
Primary completion
2010-04
Completion
2010-04

Publications

  • Results Ikushima I, Hirao K, Sasaki T, Fumiaki K, Clauson P, Roepstorff C, Haahr HL. Glucose lowering effect of IDegAsp in Japanese subjects with type 1 diabetes. 56th Annual Meeting of the Japan Diabetes Society (JDS) 2013; Country: Japan City: Kumamoto

Drugs

EvaluationDrugModalityDoseRoute
Comparator biphasic insulin aspart 30 Protein / enzyme biologic 0.5 iu/kg Subcutaneous
Subject insulin degludec/insulin aspart Unknown 0.5 iu/kg Subcutaneous